Disclaimer

Cautionary Note Regarding Forward Looking Statements:  This presentation includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the approval of CBD by the US Food and Drug Administration will lead to validation of CBD therapeutic efficacy, the projected value of the CBD market worldwide over the next two years, the expected production capacity of StillCanna’s facilities, the anticipated production cost over the next three years for StillCanna’s facility, StillCanna’s anticipated revenue over the next three years, StillCanna’s anticipated rollout of phase 4, 5 and 6.  Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur.

Forward-looking statements are based on certain material assumptions and analysis made by StillCanna and the opinions and estimates of management as of the date of this presentation, including that approval of CBD by the US Food and Drug Administration will lead to validation of CBD therapeutic efficacy, the projected value of the CBD market worldwide will be as anticipated by Cannabis Newswire, the expected production capacity of StillCanna’s facilities will be as anticipated by management, management’s assessment of the anticipated production cost over the next three years for StillCanna’s facility is accurate, management’s assessment of StillCanna’s anticipated revenue over the next three years is accurate and will be unaffected by any changes in the CBD market and StillCanna’s anticipated rollout of phase 4, 5 and 6 will be as anticipated by management.

Although StillCanna considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements.  Such risk factors may include, among others, that approval of CBD by the US Food and Drug Administration will not lead to validation of CBD therapeutic efficacy, but rather will result in evidence that CBD does not have therapeutic efficacy, the projected value of the CBD market worldwide will not be as anticipated by Cannabis Newswire, the expected production capacity of StillCanna’s facilities will not be as anticipated by management, management’s assessment of the anticipated production cost over the next three years for StillCanna’s facility is not accurate, management’s assessment of StillCanna’s anticipated revenue over the next three years is not accurate and StillCanna’s anticipated rollout of phase 4, 5 and 6 will not be as anticipated by management.

Although management of StillCanna has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes.

StillCanna does not undertake to update any forward-looking statement, forward-looking information or financial out-look that is incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.